NUDT21 and adrenal cortex carcinoma: To find whether the NUDT21 mRNA is changed at the genomic level, we show the results of CNV and SNV analysis of NUDT21 pan-cancer, which revealed that NUDT21 in ACC, has a high amplification rate, a high mutation rate in MESO, and a high profound deletion rate >1% in BRCA, while no high SNV rate was observed (Figure 3A, 3B).